The sequential decline in gross margin from 24.7% in 2026Q1 to 23.4% in 2027Q1 suggests that input cost inflation, particularly in caustic soda, is outpacing the company's ability to pass through price increases to municipal customers locked into annual contracts. Operating margin compression from 15.6% in 2025Q1 to 12.3% in 2027Q1 further indicates that SG&A growth of 8.3% year-over-year is absorbing the benefits of revenue growth. This trend may reflect a structural shift if the Industrial segment's lower-margin bulk distribution grows faster than the higher-margin Water Treatment and Health and Nutrition segments.

The sharp increase in fixed assets, likely from acquisitions and organic expansion, has not yet translated into proportional earnings growth, causing ROIC to fall from 5.6% to 3.6% over the past two years. This suggests that the company is in a period of heavy investment where returns are temporarily diluted, but the long-term payoff depends on whether the new capacity and acquired businesses can achieve the margins of the legacy Water Treatment segment. Investors should monitor whether ROIC recovers toward the 5%+ levels seen in early 2025 as these assets become fully utilized.

The improvement in CCC from 58 days in 2026Q4 to 49 days in 2027Q1 is primarily due to a reduction in DSO from 45 to 42 days, but DIO has increased from 37 to 42 days over the same period, indicating that inventory is building faster than sales. This may reflect deliberate stockpiling of chemicals ahead of anticipated price increases or slower demand in the Industrial segment. The stable DPO of 23-25 days suggests Hawkins is not stretching supplier payments, which is consistent with its conservative balance sheet but limits working capital financing.

Although leverage has nearly doubled from its 2024Q4 level, the absolute debt load remains modest, and interest coverage of 14.46x indicates that debt service is highly comfortable. The increase in debt appears to be funding the expansion in PPE and acquisitions, which could pressure returns if the investments do not generate expected cash flows. However, the D/EBITDA ratio of 4.95x in 2027Q1 is elevated relative to the 2.60x seen in 2025Q2, suggesting that EBITDA growth has not kept pace with debt accumulation, a trend that warrants monitoring.

The current ratio of 2.27 and quick ratio of 1.54 indicate that Hawkins can cover short-term obligations without relying on inventory liquidation, which is crucial given the hazardous nature of its chemical inventory. However, the minimal cash balance of $8.0M suggests that the company is operating with a thin cash buffer, relying on operating cash flow and credit lines for liquidity. Under a severe downturn, the company would likely need to draw on its credit facility, but its low leverage and strong interest coverage suggest it has ample borrowing capacity.